SI2827863T1 - Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo - Google Patents

Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo

Info

Publication number
SI2827863T1
SI2827863T1 SI201331394T SI201331394T SI2827863T1 SI 2827863 T1 SI2827863 T1 SI 2827863T1 SI 201331394 T SI201331394 T SI 201331394T SI 201331394 T SI201331394 T SI 201331394T SI 2827863 T1 SI2827863 T1 SI 2827863T1
Authority
SI
Slovenia
Prior art keywords
administration
liquid composition
patients requiring
requiring reduced
reduced volumes
Prior art date
Application number
SI201331394T
Other languages
English (en)
Inventor
Srikanth Sundaram
Scott L. Tarriff
Original Assignee
Eagle Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2827863(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals, Inc. filed Critical Eagle Pharmaceuticals, Inc.
Publication of SI2827863T1 publication Critical patent/SI2827863T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SI201331394T 2012-03-20 2013-03-15 Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo SI2827863T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US201261678715P 2012-08-02 2012-08-02
PCT/US2013/032295 WO2013142359A1 (en) 2012-03-20 2013-03-15 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
EP13765020.6A EP2827863B1 (en) 2012-03-20 2013-03-15 Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Publications (1)

Publication Number Publication Date
SI2827863T1 true SI2827863T1 (sl) 2019-06-28

Family

ID=49212373

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201332039T SI3533447T1 (sl) 2012-03-20 2013-03-15 Tekoči sestavki bendamustina za uporabo v postopku zdravljenja na bendamustin odzivnih stanj pri bolnikih,pri katerih so potrebni zmanjšani volumni za dajanje
SI201331394T SI2827863T1 (sl) 2012-03-20 2013-03-15 Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201332039T SI3533447T1 (sl) 2012-03-20 2013-03-15 Tekoči sestavki bendamustina za uporabo v postopku zdravljenja na bendamustin odzivnih stanj pri bolnikih,pri katerih so potrebni zmanjšani volumni za dajanje

Country Status (17)

Country Link
US (3) US9000021B2 (sl)
EP (3) EP4218756A1 (sl)
JP (6) JP6224064B2 (sl)
CN (2) CN107157988A (sl)
CA (1) CA2867343C (sl)
DK (2) DK2827863T3 (sl)
ES (2) ES2943668T3 (sl)
FI (1) FI3533447T3 (sl)
HK (1) HK1243346A1 (sl)
HR (2) HRP20230276T1 (sl)
HU (2) HUE062230T2 (sl)
LT (1) LT2827863T (sl)
PL (2) PL3533447T3 (sl)
PT (2) PT3533447T (sl)
RS (2) RS58744B1 (sl)
SI (2) SI3533447T1 (sl)
WO (1) WO2013142359A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
LT2827863T (lt) 2012-03-20 2019-06-10 Eagle Pharmaceuticals, Inc. Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai
PL2827862T3 (pl) * 2012-03-20 2024-05-06 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
JPWO2021014957A1 (sl) * 2019-07-22 2021-01-28
JPWO2021161876A1 (sl) * 2020-02-10 2021-08-19
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (sl) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
CA2181241C (en) 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
KR20080039954A (ko) * 2005-08-31 2008-05-07 오노 야꾸힝 고교 가부시키가이샤 점적용 주사제
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
CN103554030A (zh) 2009-01-15 2014-02-05 赛福伦公司 苯达莫司汀游离碱的新颖形式
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh) 2009-04-28 2012-04-11 赛福伦公司 苯达莫司汀的口服制剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
CN101584668A (zh) * 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2598148A4 (en) 2010-07-28 2014-05-28 Eagle Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS CONTAINING PEMETREXED HAVING EXTENDED STORAGE STABILITY
ES2784131T3 (es) 2011-12-05 2020-09-22 X Body Inc Polipéptidos de unión beta del receptor PDGF
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2864118A1 (en) 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
LT2827863T (lt) 2012-03-20 2019-06-10 Eagle Pharmaceuticals, Inc. Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai
PL2827862T3 (pl) 2012-03-20 2024-05-06 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny

Also Published As

Publication number Publication date
RS64137B1 (sr) 2023-05-31
SI3533447T1 (sl) 2023-06-30
US20150343061A1 (en) 2015-12-03
ES2718902T3 (es) 2019-07-05
US20130253026A1 (en) 2013-09-26
JP2024037915A (ja) 2024-03-19
WO2013142359A1 (en) 2013-09-26
PL2827863T3 (pl) 2019-07-31
CN107157988A (zh) 2017-09-15
LT2827863T (lt) 2019-06-10
EP3533447B1 (en) 2023-03-15
DK2827863T3 (en) 2019-04-23
PL3533447T3 (pl) 2023-07-17
CN104271135A (zh) 2015-01-07
HK1243346A1 (zh) 2018-07-13
CA2867343A1 (en) 2013-09-26
EP3533447A1 (en) 2019-09-04
EP2827863A4 (en) 2015-11-18
JP6381761B2 (ja) 2018-08-29
JP6738376B2 (ja) 2020-08-12
JP2015510940A (ja) 2015-04-13
FI3533447T3 (fi) 2023-05-04
CA2867343C (en) 2020-08-11
US20150080444A1 (en) 2015-03-19
HRP20190693T1 (hr) 2019-10-04
JP2018197248A (ja) 2018-12-13
EP2827863B1 (en) 2019-01-16
JP2022028813A (ja) 2022-02-16
US9000021B2 (en) 2015-04-07
HUE062230T2 (hu) 2023-10-28
HUE044233T2 (hu) 2019-10-28
CN104271135B (zh) 2017-05-17
EP4218756A1 (en) 2023-08-02
JP2020143143A (ja) 2020-09-10
PT3533447T (pt) 2023-05-17
PT2827863T (pt) 2019-05-13
EP2827863A1 (en) 2015-01-28
RS58744B1 (sr) 2019-06-28
ES2943668T3 (es) 2023-06-15
US9579384B2 (en) 2017-02-28
JP6224064B2 (ja) 2017-11-01
DK3533447T3 (da) 2023-04-24
HRP20230276T1 (hr) 2023-04-28
JP2018048153A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
HUE044233T2 (hu) Folyékony készítmény bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
HK1194696A1 (zh) 用於受控輸送醫用流體的系統
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
PL2773648T3 (pl) Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
PL2644215T3 (pl) Aparat do pozaustrojowej obróbki krwi
HK1210271A1 (en) Ophthalmic devices for delivery of beneficial agents
HK1172569A1 (en) Chinese medicine composition for treating colds and preparation method thereof
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
EP2832434A4 (en) METHOD FOR TREATING SIMULTANEOUS CAVITATION OF LIQUID MEDIA OF DIFFERENT COMPOSITIONS
EP2865380A4 (en) USE OF INULA LINEARIIFOLIA LACTONE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MYOCARDITIS
GB201218084D0 (en) Novel compounds and methods for use in medicine
EP2934632A4 (en) DEVICE AND METHOD FOR INHIBITING THE MOVEMENT OF A MEDICAL DEVICE IN A PATIENT
GB2508897B (en) Oxygen flow controller for medical use
IL231531A (en) Use of strigolactones and their analogues for the preparation of drugs for the treatment of cancerous growth conditions
GB201209283D0 (en) Liquid treatment
GB201209198D0 (en) Liquid treatment
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds